Electro-Capacitive Cancer Therapy(ECCT)
A groundbreaking non-invasive therapy using low-frequency electrostatic fields to target and destroy glioblastoma cells — without harming healthy brain tissue.
A New Frontier in Brain Cancer Therapy
ECCT uses low-intensity, low-frequency electrostatic waves generated by capacitance electrodes in wearable devices to target cancer cells during division — making it uniquely suited for treating glioblastoma.
Electric Field Therapy
ECCT generates precise electrostatic fields at the tumor site, disrupting the polarization of cancer cells during mitosis without affecting healthy tissue.
Non-Invasive & Safe
No surgery, no chemicals, no radiation. ECCT uses low voltage (18-30 Vpp) making it safe for daily use with zero harmful side effects.
Hyper-Personalized
Each device is custom-designed based on the patient's MRI/CT imaging data, ensuring optimal electrode placement and field distribution for their specific tumor.
Quality of Life
Treatment sessions of 2-6 hours daily at home. The wearable design allows patients to maintain their normal routine during treatment.
How ECCT Destroys Glioblastoma Cells
Cancer cells divide rapidly and are highly electrically polarized — making them uniquely vulnerable to ECCT's targeted electric fields.
Disrupting Mitosis with Electric Fields
During normal cell division, microtubules direct chromosomes to opposite poles of the cell. ECCT's electric field disrupts this polarization process, leading to mitotic arrest and programmed cell death (apoptosis).
This mechanism is particularly effective against glioblastoma cells, which have exceptionally high proliferation rates — making them more susceptible to electric field disruption than surrounding healthy brain tissue.
Induces Cancer Cell Death
Electric fields disrupt the mitotic spindle assembly, preventing cancer cells from completing division and triggering apoptosis.
Alters Membrane Ion Control
ECCT modifies ion channel activity in cancer cell membranes, enhancing drug delivery and reducing drug resistance.
Boosts Immune Response
Dead cancer cells release tumor antigens that stimulate the immune system, creating an anti-tumor immune response.
Inhibits Angiogenesis
ECCT disrupts the formation of new blood vessels that feed the tumor, cutting off its nutrient supply — critical for GBM which is highly vascularized.
Why ECCT Is Especially Promising for Glioblastoma
Glioblastoma presents unique challenges that make it an ideal candidate for electro-capacitive therapy.
Direct Brain Access
The ECCT headgear delivers electric fields directly through the skull to the tumor site. Unlike systemic chemotherapy which struggles to cross the blood-brain barrier, ECCT's electrostatic fields penetrate directly to the tumor location.
Exploits Rapid Division
GBM cells divide extremely rapidly, making them highly electrically polarized. This rapid division rate makes glioblastoma cells significantly more susceptible to ECCT's electric field disruption than slower-dividing healthy brain cells.
Targets Inoperable Tumors
Many GBM tumors are located in eloquent brain regions where surgery is too risky. ECCT can treat these inoperable tumors non-invasively, reaching locations that surgeons cannot safely access.
No Cumulative Toxicity
Unlike chemotherapy and radiation which cause cumulative damage, ECCT can be used for extended periods — critical for GBM which requires long-term treatment strategies to prevent recurrence.
Anti-Angiogenic Effect
GBM is one of the most vascularized solid tumors. ECCT's ability to inhibit new blood vessel formation cuts off the tumor's nutrient supply, a critical mechanism against GBM's aggressive growth pattern.
Synergy with Standard Treatment
ECCT can be combined with temozolomide chemotherapy and radiation, potentially enhancing their effectiveness. This multimodal approach is crucial for a cancer as aggressive as GBM.
ECCT Operating Principle
ECCT operates on the principle of generating intermediate-frequency (100-200 KHz) electric fields that interrupt the microtubule formation required for cell division. Cancer cells, which divide rapidly, are more electrically polarized than normal cells — ECCT exploits this critical vulnerability.
The ECCT Wearable Device
The ECCT system includes an electronic frequency oscillator paired with capacitive electrodes integrated into wearable apparel. For glioblastoma patients, the primary device is the treatment headgear, custom-designed based on tumor imaging data.
Your ECCT Treatment Journey
A personalized, three-step process designed around your specific tumor profile.
Tumor Localization
Based on your MRI or CT scans, the exact 3D location, size, and shape of the glioblastoma is mapped with precision.
Custom Device Design
Capacitive electrodes are custom-designed and positioned in the headgear based on your specific tumor anatomy and stage.
Optimized Treatment
Electric field distribution is calculated to ensure maximum tumor exposure at the required intensity, while sparing healthy brain tissue.
Clinical Testing & Efficacy
ECCT has undergone rigorous clinical testing with promising results in glioblastoma, breast cancer, and lung cancer.
Significant Tumor Shrinkage
Clinical trials have demonstrated significant tumor size reduction in glioblastoma patients treated with ECCT, including cases where conventional treatments had failed.
Improved Survival Rates
Patients using ECCT in combination with standard treatments have shown improved overall survival compared to standard treatment alone, with fewer side effects.
No Cumulative Toxicity
ECCT's ability to be used for extended periods without causing cumulative toxicity is a major advantage — especially for GBM which requires long-term treatment to prevent recurrence.
Synergy with Chemotherapy
ECCT enhances drug delivery by altering membrane ion control, potentially making temozolomide and other GBM chemotherapies more effective while reducing drug resistance.
Brain Cancer Survivors with ECCT
Real patients who found hope through ECCT when conventional treatments had been exhausted.
Walking Again After 2 Months with ECCT
After undergoing multiple Gamma Knife procedures for brainstem cancer, a patient lost the ability to walk or speak. With no other options left, they began ECCT treatment. Within two months, they were walking again and had regained full speech — demonstrating ECCT's incredible potential in treating difficult-to-reach brain cancers.
From Bedridden to Independent in One Month
Diagnosed with inoperable brainstem cancer and given less than six months to live, this patient was sent home bedridden. After beginning ECCT treatment with the "cancer helmet," she regained enough strength within one month to travel independently — eventually surpassing the 10-year survival milestone against all odds.
ECCT vs. Tumor Treating Fields (TTFields)
While TTFields (Optune) is FDA-approved for GBM, ECCT offers distinct advantages as an emerging alternative.
| Feature | ECCT | TTFields (Optune) |
|---|---|---|
| Contact Type | Non-contact capacitive | Direct skin contact electrodes |
| Skin Irritation | None — no skin contact | Common (requires head shaving) |
| Daily Wear Time | 2-6 hours | 18+ hours recommended |
| Personalization | Fully customized per patient | Standardized array placement |
| Cost | Significantly more affordable | ~$21,000/month |
| Applicability | All solid tumors | GBM only (FDA-approved) |
Frequently Asked Questions
How does ECCT specifically help with glioblastoma?
Can ECCT be used alongside temozolomide and radiation?
Is the ECCT headgear comfortable for daily use?
What results have been seen in brain cancer patients?
How is my ECCT device customized?
Explore ECCT for Glioblastoma
ECCT represents a promising new frontier in glioblastoma treatment. Learn more about how this non-invasive therapy could complement your treatment plan.